title: Cardiovascular disease in adult survivors of childhood cancer.
abstract: Treatment advances have increased survival in children with cancer, but subclinical, progressive, irreversible, and sometimes fatal treatment-related cardiovascular effects may appear years later. Cardio-oncologists have identified promising preventive and treatment strategies. Dexrazoxane provides long-term cardioprotection from doxorubicin-associated cardiotoxicity without compromising the efficacy of anticancer treatment. Continuous infusion of doxorubicin is as effective as bolus administration in leukemia treatment, but no evidence has indicated that it provides long-term cardioprotection; continuous infusions should be eliminated from pediatric cancer treatment. Angiotensin-converting enzyme inhibitors can delay the progression of subclinical and clinical cardiotoxicity. All survivors, regardless of whether they were treated with anthracyclines or radiation, should be monitored for systemic inflammation and the risk of premature cardiovascular disease. Echocardiographic screening must be supplemented with screening for biomarkers of cardiotoxicity and perhaps by identification of genetic susceptibilities to cardiovascular diseases; optimal strategies need to be identified. The health burden related to cancer treatment will increase as this population expands and ages.
authors.affiliation: Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201; email: vfranco@med.wayne.edu.
authors.forename: Steven E
authors.initials: SE
authors.lastname: Lipshultz
authors.forename: Vivian I
authors.initials: VI
authors.lastname: Franco
authors.forename: Tracie L
authors.initials: TL
authors.lastname: Miller
authors.forename: Steven D
authors.initials: SD
authors.lastname: Colan
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Sallan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D066126:Cardiotoxicity / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control*; D002648:Child; D064730:Dexrazoxane / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents; D002316:Cardiotonic Agents; D064730:Dexrazoxane; D004317:Doxorubicin
keywords: etiology; prevention; screening; treatment